Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...

Cross-sectional analysis of the prospective Low Vision Rehabilitation Outcomes Study included 28 US centers and assessed pre/post rehabilitation function using the Activity Inventory general ...

Tattoo-associated uveitis was once considered rare; however, that appears to be no longer true, according to a new Australian ...

MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...

The 51 st annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting will convene from March 18 to 22 in Boston. Over 1,100 attendees are expected. The venue is the Westin ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

Building on prior Ophthalmology Times coverage examining how ophthalmic drug shortages are both more frequent and longer-lasting than the national average, Ian Pitha, MD, PhD, an ophthalmologist at ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including ...

VIS-101 targets VEGF-A and ANG-2 with a bispecific tetravalent format designed to increase ligand affinity and binding capacity, aiming to improve anatomic/visual outcomes and extend dosing intervals.

Fluctuating vision is the most frequently cited complaint, exceeding classic discomfort symptoms, and may divert patients toward refractive explanations before DED is recognized and treated.

In late 2025, a group of researchers that included Maria Emfietzoglou, MD, and Victor S.M.C. Correa, MD, published a paper titled, “Inner Plexiform Layer Substrata Are Discernible with Commercial OCT ...